Progression-free survival (PFS) in oligometastatic prostate cancer improved significantly with metastasis-directed therapy ...

Dr. Barry W. Goy explains how to interpret PSA levels after prostate cancer treatment and how to manage recurrence based on ...

American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13 th and 15 th 2025, was host to the Case-Based Session: Management of ...

Increase in QOL and decrease in sexual function are among the benefits and risks, respectively, of adding SADT to EBRT for intermediate-risk prostate cancer.

Patients with high-risk prostate cancer had a significantly lower incidence of distant metastasis when treated with a ...

New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and ...

In the ongoing battle against triple negative breast cancer, Vanderbilt researchers have uncovered a promising non-invasive ...

Barry Goy, MD, provides insight into the clinical implications of a retrospective analysis examining 15-year outcomes in patients with intermediate-risk prostate cancer.

Genetically predicted rheumatoid arthritis is causally associated with prostate cancer, according to study findings.

Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk ...

A nurse-led mobile healthcare clinic identified a high proportion of clinically significant prostate cancers among men from ...

In Meraouna et al.'s study, the failure-free survival rate was 66% at 3 years of follow-up. Regarding treatment-related morbidities, 12.3% of patients experienced grade 3 genitourinary (GU) toxicity, ...